Literature DB >> 28958335

The Clinical Use of Ivabradine.

Jacob S Koruth1, Anuradha Lala2, Sean Pinney3, Vivek Y Reddy1, Srinivas R Dukkipati4.   

Abstract

The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (If) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects. Although not approved for other indications, ivabradine has also shown promise in the management of inappropriate sinus tachycardia. Here, the authors review the mechanism of action of ivabradine and salient studies that have led to its current clinical indications and use.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  angina; atrial fibrillation; bradycardia; coronary artery disease; funny current; heart failure

Mesh:

Substances:

Year:  2017        PMID: 28958335     DOI: 10.1016/j.jacc.2017.08.038

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  The hyperpolarization-activated cyclic nucleotide-gated 4 channel as a potential anti-seizure drug target.

Authors:  Qays Kharouf; A Marie Phillips; Lauren E Bleakley; Emma Morrisroe; Julia Oyrer; Linghan Jia; Andreas Ludwig; Liang Jin; Joseph A Nicolazzo; Elisabetta Cerbai; M Novella Romanelli; Steven Petrou; Christopher A Reid
Journal:  Br J Pharmacol       Date:  2020-06-17       Impact factor: 8.739

Review 2.  Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

Authors:  Miguel Pinilla-Vera; Virginia S Hahn; David A Kass
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 3.  Practical instructions for using drugs in CT and MR cardiac imaging.

Authors:  Giuseppe Rovere; Agostino Meduri; Giancarlo Savino; Francesco Ciriaco Flammia; Francesca Lo Piccolo; Maria Rachele Pia Carafa; Anna Rita Larici; Luigi Natale; Biagio Merlino; Riccardo Marano
Journal:  Radiol Med       Date:  2020-08-24       Impact factor: 3.469

Review 4.  Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week.

Authors:  Matthew A Nazari; Jared S Rosenblum; Mark C Haigney; Douglas R Rosing; Karel Pacak
Journal:  J Am Coll Cardiol       Date:  2020-07-28       Impact factor: 24.094

5.  The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.

Authors:  Camila Hartmann; Natasha Ludmila Bosch; Luara de Aragão Miguita; Elise Tierie; Lídia Zytinski; Cristina Pellegrino Baena
Journal:  Int J Clin Pharm       Date:  2018-09-01

Review 6.  How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure.

Authors:  Rose Mary Ferreira Lisboa da Silva; Anaisa Silva Roever Borges; Nilson Penha Silva; Elmiro Santos Resende; Gary Tse; Tong Liu; Leonardo Roever; Giuseppe Biondi-Zoccai
Journal:  Curr Atheroscler Rep       Date:  2018-09-17       Impact factor: 5.113

Review 7.  Ivabradine in Cardiovascular Disease Management Revisited: a Review.

Authors:  Christopher Chen; Gurleen Kaur; Puja K Mehta; Doralisa Morrone; Lucas C Godoy; Sripal Bangalore; Mandeep S Sidhu
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-07       Impact factor: 3.727

8.  The use of ivabradine in a patient with inappropriate sinus tachycardia and cardiomyopathy due to limb girdle muscular dystrophy type 2I.

Authors:  Rajkumar Rajendram; Fahad AlDhahri; Naveed Mahmood; Mubashar Kharal
Journal:  BMJ Case Rep       Date:  2020-01-21

Review 9.  Towards precision medicine in heart failure.

Authors:  Chad S Weldy; Euan A Ashley
Journal:  Nat Rev Cardiol       Date:  2021-06-09       Impact factor: 32.419

Review 10.  A pathophysiological compass to personalize antianginal drug treatment.

Authors:  Edoardo Bertero; Gerd Heusch; Thomas Münzel; Christoph Maack
Journal:  Nat Rev Cardiol       Date:  2021-07-07       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.